•
AC
ACLX
Arcellx, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
3.98B
Volume
1.21M
52W High
$94.07
52W Low
$47.86
Open
$0.00
Prev Close
$72.17
Day Range
0.00 - 0.00
About Arcellx, Inc. Common Stock
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
Latest News
CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight
GlobeNewswire Inc.•Oct 8
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
Benzinga•May 23
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight
GlobeNewswire Inc.•May 12
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
GlobeNewswire Inc.•Mar 5
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Benzinga•Feb 12
Expert Ratings For Arcellx
Benzinga•May 31
Analyst Expectations For Arcellx's Future
Benzinga•May 14
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research•May 9